References

tumors

Malignant tumours

2224-50572587-6813

Rosoncoweb

10.18027/2224-5057-2023-13-3-37-48

tumors-1167

Research Article

ОБЗОРЫ И АНАЛИТИКА

REVIEWS AND ANALYSIS

Клиническое значение альтераций MET при НМРЛ и современные возможности лекарственной терапии

Clinical significance of MET alterations in non-small cell lung cancer and currently available therapies

Смолин

С. А.

Smolin

S. А.

Сергей А. Смолин, врач-онколог, научный сотрудник отделения химиотерапии

Москва

Sergei A. Smolin, Oncologist, Research Fellow, Department of Chemotherapy

Moscow

Жукова

Л. Г.

Zhukova

L. G.

Людмила Г. Жукова, д. м. н., проф., член.-корр. РАН, заместитель директора по онкологии

Москва

Lyudmila G. Zhukova, MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director for Oncology

Moscow

Смолин

А. В.

Smolin

А. V.

Алексей В. Смолин, к. м. н., начальник радиологического центра

Москва

Aleksei V. Smolin, Head of the Radiology Center

Moscow

Бубенко

Д. Н.

Bubenko

D. N.

Дмитрий Н. Бубенко, клинический ординатор отделения химиотерапия

Москва

Dmitry N. Bubenko, Clinical Resident, Chemotherapy Department

Moscow

Гречухина

К. С.

Grechukhina

К. S.

Катерина С. Гречухина, к. м. н., заведующая химиотерапевтическим отделением; ассистент кафедры клинической онкологии

Москва

Katerina S. Grechukhina, MD, PhD, Head of the Chemotherapy Department; Assistant of the Department of Clinical Oncology

Moscow

ГБУЗ «Московский клинический научный центр им. А.С. Логинова ДЗМ»РоссияA. S. Loginov Moscow Clinical Scientific CenterRussian Federation

ФГБУ «Главный военный клинический госпиталь им. акад. Н.Н. Бурденко»РоссияN. N. Burdenko Central Military Clinical HospitalRussian Federation

ГБУЗ «Московский клинический научный центр им. А.С. Логинова ДЗМ»; ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента Российской ФедерацииРоссияA. S. Loginov Moscow Clinical Scientific Center; Central State Medical AcademyRussian Federation

2023

08112023

1333748

2023

Смолин С.А., Жукова Л.Г., Смолин А.В., Бубенко Д.Н., Гречухина К.С.

Smolin S.А., Zhukova L.G., Smolin А.V., Bubenko D.N., Grechukhina К. .

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.malignanttumors.org/jour/article/view/1167

Немелкоклеточный рак легкого (НМРЛ) является ведущей причиной смерти от рака как в России, так и во всём мире. У большинства пациентов болезнь выявляется на поздней стадии, когда возможности локальных методов лечения ограничены, а системная химиотерапия не дает выраженного, долгосрочного эффекта. Появление таргетной терапии существенно изменило парадигму лечения НМРЛ. До 60% неплоскоклеточного НМРЛ имеют те или иные генетические альтерации, потенциально являющиеся мишенью для терапии, а для 50% уже имеются одобренные лекарственные препараты. Различные варианты активации сигнального пути MET (амплификация, альтерации гена) встречаются у 2–4% пациентов НМРЛ и ассоциированы с неблагоприятным прогнозом заболевания. В последнее время удалось значительно продвинуться в разработке лекарственных препаратов способных воздействовать на этот сигнальный путь. Статья посвящена обзору наиболее важных исследований, посвящённых изучению новых терапевтических возможностей у пациентов НМРЛ с альтерацией сигнального пути МЕТ.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality both in Russia and worldwide. At diagnosis, most patients have advanced disease when the use of local treatment modalities is limited and systemic chemotherapy fails to provide a pronounced and sustained benefit. The advent of targeted therapies has significantly changed the treatment paradigm of NSCLC. Genetic alterations representing potential molecular targets have been identified in up to 60 % of non-squamous NSCLC cases, and agents directed against 50 % oncogenic targets have been approved. Various activat ing mutations of the MET signaling pathway (gene amplifications and alterations) associated with unfavorable disease outcomes occur in 2–4 % of NSCLC patients. Recently, significant advances in the development of therapies targeting this signaling pathway have been made. The article provides an overview of the key studies evaluating novel therapeutic options for NSCLC with MET alterations.

НМРЛмутация МЕТамплификация МЕТтаргетная терапия

NSCLCMET mutationMET amplificationtargeted therapy

References1

Sung, H. Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries / H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray // CA : a cancer journal for clinicians .– 2021 .– Vol. 71, iss. 3 .– P. 209–249.

Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer : A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials // Journal of Clinical Oncology .– 2008 .– Vol. 26, iss. 28 .– P. 4617–4625.

Wang, C. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer : A systematic review and meta-analysis / C. Wang, W. Qiao, Y. Jiang, M. Zhu, J. Shao, T. Wang, D. Liu, W. Li // Journal of cellular physiology .– 2020 .– Vol. 235, iss. 5 .– P. 4913–4927.

Mok, T. S. K. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial / T. S. K. Mok, Y .– L. Wu, I. Kudaba, D. M. Kowalski, B. C. Cho, H. Z. Turna, G. Castro, V. Srimuninnimit, K. K. Laktionov, I. Bondarenko, K. Kubota, G. M. Lubiniecki, J. Zhang, D. Kush, G. Lopes, G. Adamchuk, M .– J. Ahn, A. Alexandru, O. Altundag, A. Alyasova, O. Andrusenko, K. Aoe, A. Araujo, O. Aren, O. Arrieta Rodriguez, T. Ativitavas, O. Avendano, F. Barata, C. H. Barrios, C. Beato, P. Bergstrom, D. Betticher, L. Bolotina, M. Botha, S. Buddu, C. Caglevic, A. Cardona, H. Castro, F. Cay Senler, C. A. S. Cerny, A. Cesas, G .– C. Chan, J. Chang, G. Chen, X. Chen, S. Cheng, Y. Cheng, N. Cherciu, C .– H. Chiu, S. Cicenas, D. Ciurescu, G. Cohen, M. A. Costa, P. Danchaivijitr, F. de Angelis, S. J. de Azevedo, M. Dediu, T. Deliverski, P. R. M. de Marchi, F. de The Bustamante Valles, Z. Ding, B. Doganov, L. Dreosti, R. Duarte, R. Edusma-Dy, S. Emelyanov, M. Erman, Y. Fan, L. Fein, J. Feng, D. Fenton, G. Fernandes, C. Ferreira, F. A. Franke, H. Freitas, Y. Fujisaka, H. Galindo, C. Galvez, D. Ganea, N. Gil, G. Girotto, E. Goker, T. Goksel, G. Gomez Aubin, L. Gomez Wolff, H. Griph, M. Gumus, J. Hall, G. Hart, L. Havel, J. He, Y. He, C. Hernandez Hernandez, V. Hespanhol, T. Hirashima, C. M. J. Ho, A. Horiike, Y. Hosomi, K. Hotta, M. Hou, S. H. How, T .– C. Hsia, Y. Hu, M. Ichiki, F. Imamura, O. Ivashchuk, Y. Iwamoto, J. Jaal, J. Jassem, C. Jordaan, R. A. Juergens, D. Kaen, E. Kalinka-Warzocha, N. Karaseva, B. Karaszewska, A. Kazarnowicz, K. Kasahara, N. Katakami, T. Kato, T. Kawaguchi, J. H. Kim, K. Kishi, V. Kolek, M. Koleva, P. Kolman, L. Koubkova, R. Kowalyszyn, D. Kowalski, K. Koynov, D. Ksienski, T. Kurata, G. Kuusk, L. Kuzina, I. Laczo, G. E. I. Ladrera, K. Laktionov, G. Landers, S. Lazarev, G. Lerzo, K. Lesniewski Kmak, W. Li, C. K. Liam, I. Lifirenko, O. Lipatov, X. Liu, Z. Liu, S. H. Lo, V. Lopes, K. Lopez, S. Lu, G. Martinengo, L. Mas, M. Matrosova, R. Micheva, Z. Milanova, L. Miron, T. Mok, M. Molina, S. Murakami, Y. Nakahara, T. Q. Nguyen, T. Nishimura, A. Ochsenbein, T. Ohira, R. Ohman, C. K. Ong, G. Ostoros, X. Ouyang, E. Ovchinnikova, O. Ozyilkan, L. Petruzelka, X. D. Pham, P. Picon, B. Piko, A. Poltoratsky, O. Ponomarova, P. Popelkova, G. Purkalne, S. Qin, R. Ramlau, B. Rappaport, F. Rey, E. Richardet, J. Roubec, P. Ruff, A. Rusyn, H. Saka, J. Salas, M. Sandoval, L. Santos, T. Sawa, K. Seetalarom, M. Seker, N. Seki, F. Seolwane, L. Shepherd, S. Shevnya, A. K. Shimada, Y. Shparyk, I. Sinielnikov, D. Sirbu, O. Smaletz, J. P. H. Soares, A. Sookprasert, G. Speranza, V. Sriuranpong, Z. Stara, W .– C. Su, S. Suga wara, W. Szpak, K. Takahashi, N. Takigawa, H. Tanaka, J. Tan Chun Bing, Q. Tang, P. Taranov, H. Tejada, L. M. Tho, Y. Torii, D. Trukhyn, M. Turdean, H. Turna, G. Ursol, J. Vanasek, M. Varela, M. Vallejo, L. Vera, A .– P. Victorino, T. Vlasek, I. Vynnychenko, B. Wang, J. Wang, K. Wang, Y. Wu, K. Yamada, C .– H. Yang, T. Yokoyama, T. Yokoyama, H. Yoshioka, F. Yumuk, A. Zambrano, J. J. Zarba, O. Zarubenkov, M. Zemaitis, L. Zhang, X. Zhang, J. Zhao, C. Zhou, J. Zhou, Q. Zhou, A. Zippelius // The Lancet .– 2019 .– Vol. 393, iss. 10183 .– P. 1819–1830.

Seegobin, K. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR / K. Seegobin, U. Majeed, N. Wiest, R. Manochakian, Y. Lou, Y. Zhao // Frontiers in oncology .– 2021 .– Vol. 11 .– P. 750657.

Birchmeier, C. Met, metastasis, motility and more / C. Birchmeier, W. Birchmeier, E. Gherardi, G. F. Vande Woude // Nature reviews. Molecular cell biology .– 2003 .– Vol. 4, iss. 12 .– P. 915–925.

Olivero, M. Overexpression and activation of hepatocyte growth factor / scatter factor in human non-small-cell lung carcinomas / M. Olivero, M. Rizzo, R. Madeddu, C. Casadio, S. Pennacchietti, M. R. Nicotra, M. Prat, G. Maggi, N. Arena, P. G. Natali, P. M. Comoglio, M. F. Di Renzo // British journal of cancer .– 1996 .– Vol. 74, iss. 12 .– P. 1862–1868.

Ríos-Hoyo, A. Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge / A. Ríos-Hoyo, L. Moliner, E. Arriola // Cancers .– 2022 .– Vol. 14, iss. 8.

Gherardi, E. Structural basis of hepatocyte growth factor / scatter factor and MET signalling / E. Gherardi, S. Sandin, M. V. Petoukhov, J. Finch, M. E. Youles, L .– G. Ofverstedt, R. N. Miguel, T. L. Blundell, G. F. Vande Woude, U. Skoglund, D. I. Svergun // Proceedings of the National Academy of Sciences of the United States of America .– 2006 .– Vol. 103, iss. 11 .– P. 4046–4051.

Duh, F. M. Gene structure of the human MET proto-oncogene / F. M. Duh, S. W. Scherer, L. C. Tsui, M. I. Lerman, B. Zbar, L. Schmidt // Oncogene .– 1997 .– Vol. 15, iss. 13 .– P. 1583–1586.

Gentile, A. The Met tyrosine kinase receptor in development and cancer / A. Gentile, L. Trusolino, P. M. Comoglio // Cancer metastasis reviews .– 2008 .– Vol. 27, iss. 1 .– P. 85–94.

Boccaccio, C. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway / C. Boccaccio, M. Andò, L. Tamagnone, A. Bardelli, P. Michieli, C. Battistini, P. M. Comoglio // Nature .– 1998 .– Vol. 391, iss. 6664 .– P. 285–288.

Kong-Beltran, M. Somatic mutations lead to an oncogenic deletion of met in lung cancer / M. Kong-Beltran, S. Seshagiri, J. Zha, W. Zhu, K. Bhawe, N. Mendoza, T. Holcomb, K. Pujara, J. Stinson, L. Fu, C. Severin, L. Rangell, R. Schwall, L. Amler, D. Wickramasinghe, R. Yauch // Cancer research .– 2006 .– Vol. 66, iss. 1 .– P. 283–289.

Frampton, G. M. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors / G. M. Frampton, S. M. Ali, M. Rosenzweig, J. Chmielecki, X. Lu, T. M. Bauer, M. Akimov, J. A. Bufill, C. Lee, D. Jentz, R. Hoover, S .– H. I. Ou, R. Salgia, T. Brennan, Z. R. Chalmers, S. Jaeger, A. Huang, J. A. Elvin, R. Erlich, A. Fichtenholtz, K. A. Gowen, J. Greenbowe, A. Johnson, D. Khaira, C. McMahon, E. M. Sanford, S. Roels, J. White, J. Greshock, R. Schlegel, D. Lipson, R. Yelensky, D. Morosini, J. S. Ross, E. Collisson, M. Peters, P. J. Stephens, V. A. Miller // Cancer discovery .– 2015 .– Vol. 5, iss. 8 .– P. 850–859.

Schrock, A. B. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations / A. B. Schrock, G. M. Frampton, J. Suh, Z. R. Chalmers, M. Rosenzweig, R. L. Erlich, B. Halmos, J. Goldman, P. Forde, K. Leuenberger, N. Peled, G. P. Kalemkerian, J. S. Ross, P. J. Stephens, V. A. Miller, S. M. Ali, S .– H. I. Ou // Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer .– 2016 .– Vol. 11, iss. 9 .– P. 1493–1502.

Tong, J. H. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis / J. H. Tong, S. F. Yeung, A. W. H. Chan, L. Y. Chung, S. L. Chau, R. W. M. Lung, C. Y. Tong, C. Chow, E. K. Y. Tin, Y. H. Yu, H. Li, Y. Pan, W. P. Chak, C. S. H. Ng, T. S. K. Mok, K. F. To // Clinical cancer research : an official journal of the American Association for Cancer Research .– 2016 .– Vol. 22, iss. 12 .– P. 3048–3056.

Paik, P. K. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping / P. K. Paik, A. Drilon, P .– D. Fan, H. Yu, N. Rekhtman, M. S. Ginsberg, L. Borsu, N. Schultz, M. F. Berger, C. M. Rudin, M. Ladanyi // Cancer discovery .– 2015 .– Vol. 5, iss. 8 .– P. 842–849.

Kawakami, H. Targeting MET Amplification as a New Oncogenic Driver / H. Kawakami, I. Okamoto, W. Okamoto, J. Tanizaki, K. Nakagawa, K. Nishio // Cancers .– 2014 .– Vol. 6, iss. 3 .– P. 1540–1552.

Engelman, J. A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling / J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C .– M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Jänne // Science (New York, N. Y.) .– 2007 .– Vol. 316, iss. 5827 .– P. 1039–1043.

Go, H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer / H. Go, Y. K. Jeon, H. J. Park, S .– W. Sung, J .– W. Seo, D. H. Chung // Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer .– 2010 .– Vol. 5, iss. 3 .– P. 305–313.

Caparica, R. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations / R. Caparica, C. T. Yen, R. Coudry, S .– H. I. Ou, M. Varella-Garcia, D. R. Camidge, G. de Castro // Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer .– 2017 .– Vol. 12, iss. 1 .– P. 141–144.

Ou, S .– H. I. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification / S .– H. I. Ou, E. L. Kwak, C. Siwak-Tapp, J. Dy, K. Bergethon, J. W. Clark, D. R. Camidge, B. J. Solomon, R. G. Maki, Y .– J. Bang, D .– W. Kim, J. Christensen, W. Tan, K. D. Wilner, R. Salgia, A. J. Iafrate // Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer .– 2011 .– Vol. 6, iss. 5 .– P. 942–946.

Davies, K. D. Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion / K. D. Davies, T. L. Ng, A. Estrada-Bernal, A. T. Le, P. R. Ennever, D. R. Camidge, R. C. Doebele, D. L. Aisner // JCO precision oncology .– 2017 .– Vol. 2017, iss. 1.

Danilkovitch-Miagkova, A. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors / A. Danilkovitch-Miagkova, B. Zbar // Journal of Clinical Investigation .– 2002 .– Т. 109, № 7 .– С. 863–867.

Park, S. High MET copy number and MET overexpression : poor outcome in non-small cell lung cancer patients / S. Park, Y .– L. Choi, C. O. Sung, J. An, J. Seo, M .– J. Ahn, J. S. Ahn, K. Park, Y. K. Shin, O. C. Erkin, K. Song, J. Kim, Y. M. Shim, J. Han // Histology and histopathology .– 2012 .– Vol. 27, iss. 2 .– P. 197–207.

Kwon, D. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas : An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics / D. Kwon, J. Koh, S. Kim, H. Go, Y. A. Kim, B. Keam, T. M. Kim, D .– W. Kim, Y. K. Jeon, D. H. Chung // Lung cancer (Amsterdam, Netherlands) .– 2017 .– Vol. 106 .– P. 131–137.

Spigel, D. R. Treatment Rationale Study Design for the MetLung Trial : A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer / D. R. Spigel, M. J. Edelman, T. Mok, K. O’Byrne, L. Paz-Ares, W. Yu, K. Rittweger, H. Thurm // Clinical lung cancer .– 2012 .– Vol. 13, iss. 6 .– P. 500–504.

Scagliotti, G. V. Rationale and design of MARQUEE : a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer / G. V. Scagliotti, S. Novello, J. H. Schiller, V. Hirsh, L. V. Sequist, J .– C. Soria, J. von Pawel, B. Schwartz, R. von Roemeling, A. B. Sandler // Clinical lung cancer .– 2012 .– Vol. 13, iss. 5 .– P. 391–395.

Camidge, D. R. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC) / D. R. Camidge, J. Bar, H. Horinouchi, J. W. Goldman, F. V. Moiseenko, E. Filippova, I. Cicin, P. A. Bradbury, N. Daaboul, P. Tomasini, T .– E. Ciuleanu, D. Planchard, M. Moskovitz, N. Girard, J. Y. Jin, M. Dunbar, E. Bolotin, J. Looman, C. Ratajczak, S. Lu // Journal of Clinical Oncology .– 2022 .– Т. 40, 16_suppl .– С. 9016.

Neal, J. W. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512) : a randomised, controlled, open-label, multicentre, phase 2 trial / J. W. Neal, S. E. Dahlberg, H. A. Wakelee, S. C. Aisner, M. Bowden, Y. Huang, D. P. Carbone, G. J. Gerstner, R. E. Lerner, J. L. Rubin, T. K. Owonikoko, P. J. Stella, P. D. Steen, A. A. Khalid, S. S. Ramalingam // The Lancet. Oncology .– 2016 .– Vol. 17, iss. 12 .– P. 1661–1671.

Camidge, D. R. Efficacy and safety of crizotinib in patients with advanced c-MET -amplified non-small cell lung cancer (NSCLC) / D. R. Camidge, S .– H. I. Ou, G. Shapiro, G. A. Otterson, L. C. Villaruz, M. A. Villalona-Calero, A. J. Iafrate, M. Varella-Garcia, S. Dacic, S. Cardarella, W. Zhao, L. Tye, P. Stephenson, K. D. Wilner, L. P. James, M. A. Socinski // Journal of Clinical Oncology .– 2014 .– Т. 32, 15_suppl .– С. 8001.

Zou, H. Y. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms / H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P .– P. Kung, M. D. Nambu, G. Los, S. L. Bender, B. Mroczkowski, J. G. Christensen // Cancer research .– 2007 .– Vol. 67, iss. 9 .– P. 4408–4417.

Shalata, W. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer : A Retrospective, Single Institution Experience / W. Shalata, A. Yakobson, S. Weissmann, E. Oscar, M. Iraqi, W. Kian, N. Peled, A. Agbarya // Oncology .– 2022 .– Vol. 100, iss. 9 .– P. 467–474.

Lara, M. S. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer / M. S. Lara, W. S. Holland, D. Chinn, R. A. Burich, P. N. Lara, D. R. Gandara, K. Kelly, P. C. Mack // Clinical lung cancer .– 2017 .– Vol. 18, iss. 3 .– P. 281–285.

Jürgen Wolf, M. D., Takashi Seto, M. D., Ji-Youn Han, M. D., Ph. D., Noemi Reguart, M. D., Ph. D., Edward B. Garon, M. D., Harry J. M. Groen, M. D., Ph. D., Daniel S. W. Tan, M. D., Ph. D., Toyoaki Hida, M. D., Ph. D., Maja de Jonge, M. D., Ph. D., Sergey V. Orlov, M. D., Egbert F. Smit, M. D., Ph. D., Pierre-Jean Souquet, M. D., et al. Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer / Jürgen Wolf, M. D., Takashi Seto, M. D., Ji-Youn Han, M. D., Ph. D., Noemi Reguart, M. D., Ph. D., Edward B. Garon, M. D., Harry J. M. Groen, M. D., Ph. D., Daniel S. W. Tan, M. D., Ph. D., Toyoaki Hida, M. D., Ph. D., Maja de Jonge, M. D., Ph. D., Sergey V. Orlov, M. D., Egbert F. Smit, M. D., Ph. D., Pierre-Jean Souquet, M. D., et al. // N Engl J Med .– 03.09.2020 .– Т. 383 .– С. 2020.

Illini, O. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program / O. Illini, H. Fabikan, A. Swalduz, A. Vikström, D. Krenbek, M. Schumacher, E. Dudnik, M. Studnicka, R. Öhman, R. Wurm, L. Wannesson, N. Peled, W. Kian, J. Bar, S. Daher, A. Addeo, O. Rotem, G. Pall, A. Zer, A. Saad, T. Cufer, H. G. Sorotsky, S. M. S. Hashemi, K. Mohorcic, R. Stoff, Y. Rovitsky, S. Keren-Rosenberg, T. Winder, C. Weinlinger, A. Valipour, M. J. Hochmair // Therapeutic advances in medical oncology .– 2022 .– Vol. 14 .– 17588359221103206.

Friese-Hamim, M. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models / M. Friese-Hamim, F. Bladt, G. Locatelli, U. Stammberger, A. Blaukat // American Journal of Cancer Research .– 2017 .– Vol. 7, iss. 4 .– P. 962–972.

Le, X. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC : Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice / X. Le, H. Sakai, E. Felip, R. Veillon, M. C. Garassino, J. Raskin, A. B. Cortot, S. Viteri, J. Mazieres, E. F. Smit, M. Thomas, W. T. Iams, B. C. Cho, H. R. Kim, J. C .– H. Yang, Y .– M. Chen, J. D. Patel, C. M. Bestvina, K. Park, F. Griesinger, M. Johnson, M. Gottfried, C. Britschgi, J. Heymach, E. Sikoglu, K. Berghoff, K .– M. Schumacher, R. Bruns, G. Otto, P. K. Paik // Clinical cancer research : an official journal of the American Association for Cancer Research .– 2022 .– Vol. 28, iss. 6 .– P. 1117–1126.

Ahn, M. P1.01–134 SAVANNAH : Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib / M. Ahn, M. Cantarini, P. Frewer, G. Hawkins, J. Peters, P. Howarth, G. Ahmed, T. Sahota, R. Hartmaier, X. Li-Sucholeiki, G. Oxnard // Journal of Thoracic Oncology .– 2019 .– Т. 14, № 10 .– S415-S416.

Zaborowska-Szmi, M. Savolitinib for non-small cell lung cancer / M. Zaborowska-Szmi, S. Szmit, M. Krzakowski, D. M. Kowalski // Drugs of today (Barcelona, Spain : 1998) .– 2023 .– Vol. 59, iss. 1 .– P. 17–36.

Miranda, O. Status of Agents Targeting the HGF / c-Met Axis in Lung Cancer / O. Miranda, M. Farooqui, J. M. Siegfried // Cancers .– 2018 .– Vol. 10, iss. 9.

Murakami, H. Preliminary Results of Safety and PK of Telisotuzumab Vedotin (T) in Japanese Patients with Advanced Solid Tumors / H. Murakami, K. Wakuda, H. Kenmotsu, A. Todaka, T. Yokota, N. Yamamoto, T. Shimizu, A. Shimomura, K. Yonemori, C. Ocampo, A. Parikh, K. Fukasawa, I. Matsumoto, K. Suzuki, Y. Fujiwara // Annals of Oncology .– 2019 .– Т. 30 .– vi125.

The authors declare that there are no conflicts of interest present.